In this space, we’ve talked a great deal about ICER’s failure – often its refusal – to consider the needs and perspectives of patients when determining the value of a new drug or treatment. Patients Rising recently produced a short video about a meeting in 2019 about treatments for Duchenne muscular dystrophy where those problems were on full display.

Click here to learn more about ICER’s process and methodology.